Needle Exchange Programs Lower HIV Risk: Panel

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 10
Volume 4
Issue 10

WASHINGTON-Programs designed to encourage drug addicts not to share needles can help reduce the spread of HIV, a National Academy of Sciences panel said in its report to Congress. The report may pave the way for a change in government policy to allow the use of federal funds to support such programs.

WASHINGTON-Programs designed to encourage drug addicts not toshare needles can help reduce the spread of HIV, a National Academyof Sciences panel said in its report to Congress. The report maypave the way for a change in government policy to allow the useof federal funds to support such programs.

The panel, organized by the academy's National Research Counciland the Institute of Medicine, said that exchange programs orprograms that distribute bleach to addicts for use in sterilizingneedles can effectively decrease the risk of HIV without encouragingdrug use.

Dr. Lincoln E. Moses, chairman of the panel and professor emeritusat Stanford University, said that a New Haven, Conn, program sawa one third decrease in the rate of HIV contamination in needlesturned in for exchange. A Tacoma, Wash, program showed an eightfolddecrease in hepatitis, which can be used as an indictor of HIVamong IV drug users.

Bonding Ritual or Necessity?

The report also put to rest the notion that addicts share needlesas a form of bonding ritual and would not stop the practice evenif new needles were available. Dr. Steven Koester, an anthropologistat the University of Colorado, told the panel that addicts shareneedles out of necessity to avoid being caught carrying illegaldrug paraphernalia.

To get off the street as quickly as possible after purchasingdrugs, addicts go to a "shooting gallery" where onlyused needles are available. If new needles were accessible andlegal, addicts would use them, not only to avoid the risk of HIVinfection but also the discomfort and damage to veins caused byblunted or clogged needles, Dr. Koester said.

Recent Videos
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Related Content